Search
Ventyx Biosciences Inc
VTYXAdd to Watchlist
14.000USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.00BMarket Cap
LossP/E TTM
More Details of Ventyx Biosciences Inc Company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Ventyx Biosciences Inc Info
Ticker SymbolVTYX
Company nameVentyx Biosciences Inc
IPO dateOct 21, 2021
CEOMohan (Raju)
Number of employees79
Security typeOrdinary Share
Fiscal year-endOct 21
Address12790 El Camino Real, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone17604076511
Websitehttps://ventyxbio.com/
Ticker SymbolVTYX
IPO dateOct 21, 2021
CEOMohan (Raju)
Company Executives of Ventyx Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
-100.00%
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Mr. William R. White, J.D.
Mr. William R. White, J.D.
Independent Director
Independent Director
--
--
Ms. Onaiza Cadoret - Manier
Ms. Onaiza Cadoret - Manier
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Moore
Mr. Matthew (Matt) Moore
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Roy M. Gonzales
Mr. Roy M. Gonzales
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
-100.00%
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Mr. William R. White, J.D.
Mr. William R. White, J.D.
Independent Director
Independent Director
--
--
Ms. Onaiza Cadoret - Manier
Ms. Onaiza Cadoret - Manier
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Ventyx Biosciences Inc?
The top five shareholders of Ventyx Biosciences Inc are: Dr. Sheila Gujrathi, M.D.
How many institutions hold shares of Ventyx Biosciences Inc (VTYX)?
As of 2025Q4, 321 institutions hold shares of Ventyx Biosciences Inc, with a combined market value of approximately 51.24M, accounting for 71.45% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -33340989.00.